Back to top
more

Nevro (NVRO)

(Delayed Data from NYSE)

$4.92 USD

4.92
240,529

+0.09 (1.86%)

Updated Oct 14, 2024 04:00 PM ET

After-Market: $4.90 -0.02 (-0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (96 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

What's in Store for GW Pharmaceuticals' (GWPH) Q4 Earnings?

GW Pharmaceuticals (GWPH) Q4 results likely to reflect top-line growth on strong adoption of Epidiolex and Sativex.

What's in Store for SmileDirectClub's (SDC) Q4 Earnings?

SmileDirectClub (SDC) is likely to have gained from a strong international presence in Q4.

Can Dental Growth Drive Henry Schein's (HSIC) Q4 Earnings?

Consistent contribution from Henry Schein One is likely to have benefited Henry Schein's (HSIC) Q4 performance.

Trina Mukherjee headshot

3 Medical Product Stocks Likely to Beat This Earnings Season

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Sonoco (SON) Meets Q4 Earnings Estimates

Sonoco (SON) delivered earnings and revenue surprises of 0.00% and 0.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

HealthEquity (HQY) to Report Q4 Earnings: What's in Store?

HealthEquity's (HQY) fourth-quarter fiscal 2020 earnings are likely to reflect top-line growth and higher HSA member growth.

Global Industrial Unit to Drive Ecolab's (ECL) Q4 Earnings

Ecolab's (ECL) Q4 results are likely to reflect strength in core Global Industrial unit.

Medtronic (MDT) to Report Q3 Earnings: What's in Store?

In the fiscal third quarter, Medtronic (MDT) is expected to have registered strong growth for TAVR across the United States, courtesy of its higher adoption by the low-risk patient population.

Can Pharmacy Services Growth Aid CVS Health (CVS) Q4 Earnings?

Expanded claims volume and better purchasing economics are expected to have aided CVS Health's (CVS) top line in Q4.

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

DexCom's (DXCM) fourth-quarter earnings are likely to reflect top-line growth and rising global awareness of the company's real-time CGM.

Cannabis Therapy to Drive Canopy Growth's (CGC) Q3 Earnings

Key acquisitions are expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal third quarter

What's in the Offing for LabCorp's (LH) Earnings in Q4?

With near-term visibility seeming bleak at the moment, we anticipate PAMA to once again dent LabCorp's (LH) fourth-quarter top line.

Here's Why You Should Hold on to Nevro (NVRO) Stock for Now

Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results

Higher revenues and upbeat 2020 worldwide revenue outlook benefit Nevro's (NVRO) preliminary Q4 results.

Nevro (NVRO) Hits New 52-Week High: What's Driving the Stock?

Nevro (NVRO) gains from several positive developments.

Why Is Nevro (NVRO) Up 9.6% Since Last Earnings Report?

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Nevro (NVRO) Stock for Now

Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

Company News For Nov 8, 2019

Companies In The News Are: GDDY, INSG, NVRO, TRIP

Nevro (NVRO) Q3 Loss Narrower Than Expected, Revenues Up Y/Y

Nevro (NVRO) launches the Senza Omnia SCS System commercially in the United States in Q3.

Nevro (NVRO) Reports Q3 Loss, Tops Revenue Estimates

Nevro (NVRO) delivered earnings and revenue surprises of 31.76% and 6.21%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Nevro (NVRO) Q3 Earnings Expected to Decline

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Hold on to Nevro (NVRO) Stock for Now

Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

Why Is Nevro (NVRO) Up 37.7% Since Last Earnings Report?

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.